SAN FRANCISCO, Jan. 3, 2018 /PRNewswire/ -- Nektar
Therapeutics' (Nasdaq: NKTR) President and Chief Executive
Officer, Howard Robin, is scheduled to present at the upcoming
36th Annual J.P. Morgan Healthcare Conference in San
Francisco on Tuesday, January 9, 2018 at 11:00
a.m. Pacific Time.
The presentation will be accessible via a Webcast through a link
posted on the Investors, Events Calendar section of
the Nektar website: http://ir.nektar.com/events.cfm.
In addition, the company will webcast the Q&A breakout session
immediately following its presentation at 11:30 a.m. Pacific
Time. This Webcast will be available for replay until February
20, 2018.
About Nektar
Nektar Therapeutics is a research-based, development stage
biopharmaceutical company whose mission is to discover and develop
innovative medicines to address the unmet medical needs of
patients. Our R&D pipeline of new investigational medicines
includes treatments for cancer, auto-immune disease and chronic
pain. We leverage Nektar's proprietary and proven chemistry
platform in the discovery and design of our new therapeutic
candidates. Nektar is headquartered in San
Francisco, California, with additional operations
in Huntsville, Alabama and Hyderabad, India.
Further information about the company and its drug development
programs and capabilities may be found online
at http://www.nektar.com.
Contact:
Investors
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
View original
content:http://www.prnewswire.com/news-releases/nektar-therapeutics-president-and-ceo-howard-robin-to-present-at-the-36th-annual-jp-morgan-healthcare-conference-in-san-francisco-ca-300576786.html
SOURCE Nektar Therapeutics